These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 9840211)
1. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Han KS; Kim YG; Yoo JK; Lee JW; Lee MG Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211 [TBL] [Abstract][Full Text] [Related]
2. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect. Kim EJ; Kim SO; Lee DH; Lim H; Lee MG Biopharm Drug Dispos; 2001 Apr; 22(3):119-28. PubMed ID: 11745914 [TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats. Kim J; Kim EJ; Han KS; Chang MS; Lee MG J Pharm Pharmacol; 1999 Sep; 51(9):1031-6. PubMed ID: 10528986 [TBL] [Abstract][Full Text] [Related]
4. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. Yu SY; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG J Pharm Sci; 2003 Aug; 92(8):1592-603. PubMed ID: 12884246 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects. Kim SH; Lee MG Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504 [TBL] [Abstract][Full Text] [Related]
7. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects. Han KS; Lee MG Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506 [TBL] [Abstract][Full Text] [Related]
9. Hepatic and intestinal first-pass effects of oltipraz in rats. Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. Yu KS; Bae KS; Shon JH; Cho JY; Yi SY; Chung JY; Lim HS; Jang IJ; Shin SG; Song KS; Moon BS J Clin Pharmacol; 2004 Jan; 44(1):73-82. PubMed ID: 14681344 [TBL] [Abstract][Full Text] [Related]
11. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. Choi YH; Kim SG; Lee MG J Pharm Sci; 2006 Nov; 95(11):2543-52. PubMed ID: 16937336 [TBL] [Abstract][Full Text] [Related]
12. Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect. Kim EJ; Bae SK; Kim HJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG J Pharm Sci; 2003 May; 92(5):1112-24. PubMed ID: 12712431 [TBL] [Abstract][Full Text] [Related]
13. The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. Li H; Chung SJ; Kim DC; Kim HS; Lee JW; Shim CK Drug Metab Dispos; 2001 Jan; 29(1):54-9. PubMed ID: 11124230 [TBL] [Abstract][Full Text] [Related]
14. Liver and gastrointestinal first-pass effects of azosemide in rats. Kim J; Kim SH; Lee MG J Pharm Pharmacol; 1997 Sep; 49(9):878-83. PubMed ID: 9306255 [TBL] [Abstract][Full Text] [Related]
15. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats. Kim J; Han KS; Lee JW; Lee MG Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504 [TBL] [Abstract][Full Text] [Related]
16. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability. Lee JH; Lee MG J Pharm Pharm Sci; 2007; 10(1):37-50. PubMed ID: 17498392 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Shin HS; Bae SK; Lee MG Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145 [TBL] [Abstract][Full Text] [Related]
18. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Choi YH; Lee YS; Bae SH; Kim TK; Lee BY; Lee MG Biopharm Drug Dispos; 2009 Sep; 30(6):305-17. PubMed ID: 19639551 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Shin JH; Choi KY; Kim YC; Lee MG Antimicrob Agents Chemother; 2004 May; 48(5):1756-62. PubMed ID: 15105131 [TBL] [Abstract][Full Text] [Related]
20. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Yang SH; Lee MG Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]